Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC): Marker Performance Validation and Technical Development Study

NCT03804593 is registered in ClinicalTrials.gov with Epigenomics, Inc as lead sponsor.

NCT NCT03804593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03804593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC): Marker Performance Validation and Technical Development Study
Lead sponsor
Epigenomics, Inc
Phase
Observational
Overall status
Completed
Start date
December 17, 2018
Completion date
October 31, 2019
Enrollment
175 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, liver, hepatic cirrhosis, hepatocellular carcinoma, liver cancer